Celltex Executive Team

David G. Eller

Chairman, Co-Founder, and Chief Executive Officer

David Eller has a career in senior management which spans over 35 years, serving as President of DuPont Pharmaceuticals–Europe; Chief Executive Officer and President of Virbac Corporation; and Founder, Chairman and Chief Executive Officer of Granada Corporation and American National Petroleum Corporation, among others. He also served as Chairman of the Board of Regents of the Texas A&M University System, as well as simultaneously holding the position of Chancellor for a period.

Mr. Eller currently or previously served on numerous boards, some of which are the Boards of Baylor College of Medicine, Biowish Technologies, the Foundation for Biomedical Research, Rice University Energy & Environmental Systems Institute, Memorial Hermann Hospital, Texas Chamber of Commerce, and Allied Bancshares.

He has received a number of awards and honors, including the Medallion of Entrepreneurship, Beta Gamma Sigma National Entrepreneur of the Year Award, the Ernst & Young Entrepreneur of the Year Award and the Enterprise Award for work in the biotechnology and life science fields. Other honors include receiving the Paul Harris Award from Rotary International, the first in the history of the University to receive the title of Chairman Emeritus of the Texas A&M University System and having a major research building on the Texas A&M University campus named in his honor.

Mr. Eller is a graduate of Texas A&M University, the Stanford Graduate School of Business Executive Program and the Harvard Business School Advanced Management Program. He served as officer on active duty in the U. S. Army Corps of Engineers-Germany.

Dr. Stanley Jones

M.D., Co-Founder, Chief Medical Officer

Dr. Stanley Jones, M.D. is an orthopedic spine surgeon who has an active spine practice in the State of Texas, and is a board certified member of the American Board of Orthopedic Surgery.

Dr. Jones received a B.A. degree in chemistry from Texas Tech University and an M.D. degree from the University of Texas Southwestern Medical School. He completed an internship at the University of Utah and an orthopedic residency at the University of Texas Medical School in Houston. He then served in the U.S. Army as a Captain in the Medical Corp.

Dr. Jones has served as President of the International Intradiscal Therapy Society, President of the Texas Spine Society, and was previously a Director of Memorial Hermann Hospital Systems Spine Surgery program. He is an active member of the North American Spine Society and the American Academy of Orthopedic Surgery.

Dr. Jones’ current interests are in the field of minimally invasive spine surgery, pain management, and the use of autologous, adult mesenchymal stem cells for medical benefits to patients.

In 2009, Dr. Jones suffered from a sudden onset of debilitating autoimmune psoriatic arthritis. Although he continued to see patients, his condition prevented him from performing surgery at his full capacity. He was forced to reduce his surgical load by 75%. Dr. Jones located a company in Seoul, South Korea, that had developed a state-of-the-art technology which allowed him to receive the treatment of his own stem cells. Four months after receiving his stem cells, he was able to return to a normal surgery schedule and a life without pain. Dr. Jones is responsible for bringing stem cell technology to Texas from overseas.

David Erik Eller

Vice President Operations

Mr. Eller has over 20 years of experience in starting, building, and selling businesses. His general experience includes managing several different and diverse enterprises, including biotechnology, communications, asset holdings and veterinary therapeutic medicine. His relevant experience includes corporate finance, capital raise, P&L management, strategy formulation, planning, and implementation, project management, operations management, cGMP laboratory management, marketing, sales and overall general management. He has had broad based leadership roles in most of his endeavors, and continues on that path with Celltex Therapeutics as the head of Operations. He is currently involved with, or worked for, Anistem LLC – veterinary stem cell therapy, Enron Corp – Asia Pacific, AT&T Global Markets, CoBalt Broadband Corporation, Bechtel, among others. Erik received his BS in Political Science and Business Administration from Texas A&M University in College Station, Texas. He also earned an MBA from Texas A&M University, and a mini-MBA from the Wharton School of Business.

Dr. Jane S. Young

M.D., Ph.D., Chief Scientific Officer

Dr. Young is a medical doctor with over twenty years of clinical, laboratory, research, and product development experience. She has extensive academic experience in cell biology, molecular biology, protein science, biochemistry, and animal models. Prior to joining Celltex she served as the senior scientist and associate research scientist for PPD Inc., a leading global contract research organization, where she expanded her industry GMP experience doing drug analysis. Dr. Young has a track record of performing and leading projects in areas of genetic mutation and deletion analysis, molecular hematology, FISH probe design and analysis, recombinant protein and kinetics analysis, development and optimization of laboratory assays, cell sorting and flow cytometry analysis, drug trials and animal models. She has demonstrated her comprehensive knowledge through chapter in two scientific books and twenty-five publications she has authored. Dr. Young graduated from Zhejiang University School of Medicine in China, and has practiced internal medicine for four years. She received her PhD in 1999 from Lund University, Sweden. Dr. Young completed a post-doctoral fellowship and served as a research specialist at the Howard Hughes Medical Institute, Department of Hematology and Medical Oncology.